Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies Pharmaceutical Investing
Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022 Pharmaceutical Investing
Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials Pharmaceutical Investing
For World Sight Day, new app available for Canadians living with glaucoma, the Silent Thief of Sight Pharmaceutical Investing
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older Life Science Investing
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age Life Science Investing
Abbott and The Home Edit Redesign the Medicine Cabinet to Help People Prepare for the Upcoming Virus Season Pharmaceutical Investing
BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients Pharmaceutical Investing
SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION Pharmaceutical Investing
Health Canada Approves KEYTRUDA® as monotherapy for the adjuvant treatment of adults with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions Life Science Investing
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead's Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer Pharmaceutical Investing
